Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New decision tool aims to reduce aggressive End-of-Life cancer care

NCT ID NCT04823377

Knowledge-focused Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a special decision-making tool can help doctors and patients with advanced non-small cell lung cancer decide when to stop cancer treatments. The goal is to reduce the number of patients receiving chemotherapy or other treatments in their last days of life, which can be harsh and offer little benefit. The study compares usual care to a period where the tool is used, involving 364 participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide a reliable way to help doctors and patients decide when to stop cancer treatments, potentially improving quality of life at the end of life.
What could go wrong
This is an observational-style study comparing two time periods, not a randomized trial, so results may be influenced by other changes over time. It does not test a new drug or treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 364 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically or cytologically proven non-small-cell lung carcinoma (NSCLC) including NSCLC with oncogene addiction. 2. Stage IV or IIB/IIIC non irradiable (8th classification TNM, UICC 2015) 3. Patient having completed at least one line of chemotherapy in the context of metastatic disease (or in the context of locoregional disease if the last chemotherapy was less than 6 months ago). 4. ECOG Performance Status ≥ 2. 5. Age ≥ 18. 6. Written informed consent. 7. Patient capable, according to the investigator, to comply with the requirements of the study. Exclusion Criteria: 1. Small Cell Lung Cancer (including mixed forms). 2. Patient with NSCLC for whom a decision has already been made to permanently discontinue all systemic cancer treatment. 3. Impossible follow up for geographical, social or psychological reason. 4. Inability to answer a questionnaire (language or neurological barrier). 5. Patient under guardianship. 6. Patient being treated in a therapeutic trial. 7. Patient not covered by social security. -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced cancer Carcinoma, non-small-cell lung

Contacts and locations

Locations

  • AP-HP Ambroise Paré

    Boulogne-Billancourt, 92100, France

  • AP-HP Bichat

    Paris, 75018, France

  • AP-HP Cochin

    Paris, 75014, France

  • AP-HP Tenon

    Paris, 75970, France

  • CGFL

    Dijon, 21000, France

  • CH Abbeville

    Abbeville, 80142, France

  • CH Henri Duffaut Avignon

    Avignon, 84000, France

  • CH Intercommunal de Créteil

    Créteil, 94000, France

  • CH Saint-Malo

    St-Malo, 35420, France

  • CH du Pays d'Aix

    Aix-en-Provence, 13616, France

  • CHD Vendée

    La Roche-sur-Yon, 85925, France

  • CHI de Compiègne-Noyon

    Compiègne, 60200, France

  • CHR Metz-Thionville - Hôpital de Mercy

    Ars-Laquenexy, France

  • CHRU Lille

    Lille, 59000, France

  • CHU Amiens - Hôpital Sud

    Amiens, 80054, France

  • CHU Angers

    Angers, 49933, France

  • CHU Grenoble Alpes

    Grenoble, 38043, France

  • CHU Sud Francilien

    Corbeil-Essonnes, 91100, France

  • Centre Léon Bérard

    Lyon, 69008, France

  • Clinique Tessier

    Valenciennes, 59300, France

  • Clinique des Cèdres

    Cornebarrieu, 31700, France

  • Hôpital Foch

    Suresnes, 92150, France

  • Institut Curie

    Paris, 75005, France

  • Institut Curie

    Saint-Cloud, 92210, France

  • Institut Sainte-Catherine

    Avignon, 84918, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.